Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Non-Current Assets (2016 - 2025)

IGC Pharma (IGC) has disclosed Non-Current Assets for 15 consecutive years, with $7.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets rose 26.47% to $7.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.7 million, a 26.47% increase, with the full-year FY2025 number at $5.9 million, down 5.58% from a year prior.
  • Non-Current Assets was $7.7 million for Q3 2025 at IGC Pharma, up from $5.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $12.4 million in Q1 2021 to a low of $5.8 million in Q2 2025.
  • A 5-year average of $9.3 million and a median of $10.6 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: plummeted 42.15% in 2024, then increased 26.47% in 2025.
  • IGC Pharma's Non-Current Assets stood at $12.1 million in 2021, then decreased by 11.08% to $10.7 million in 2022, then fell by 28.37% to $7.7 million in 2023, then dropped by 21.48% to $6.0 million in 2024, then increased by 28.41% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Non-Current Assets are $7.7 million (Q3 2025), $5.8 million (Q2 2025), and $5.9 million (Q1 2025).